GAL and arthritic joint disease: One study reported a milder course of arthritis when a CCR1 antagonist was applied (CCR1 is a CCL3 receptor), and linked the expression of CCL3 to other chronic inflammatory diseases.33 Taking these findings together, galanin treatment weakens correlations of CCL3 with other cytokines, possibly to downregulate the acute immune response.